or Try an Advanced Search...

    Technical Analysis for REPL - Replimune Group, Inc.

    Grade Last Price % Change Price Change
    C 11.23 2.56% 0.28
    REPL closed up 2.56 percent on Wednesday, November 20, 2024, on 81 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical REPL trend table...
    Date Alert Name Type % Chg
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Stochastic Buy Signal Bullish 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness 2.56%
    Outside Day Range Expansion 2.56%
    Lower Bollinger Band Touch Weakness 2.56%
    Oversold Stochastic Weakness 2.56%
    MACD Bearish Centerline Cross Bearish 4.27%
    Older End-of-Day Signals for REPL ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 20 hours ago
    Up 2% about 21 hours ago
    60 Minute Opening Range Breakout about 21 hours ago
    Up 1% about 22 hours ago
    Rose Above Previous Day's High about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    REPL Chart by TradingView
    Basic chart:

    Profile

    Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapy Products Oncolytic Virus Experimental Cancer Treatments Transgene Sa Akseli Hemminki Rp1

    Is REPL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 Replimune Group GAAP EPS of -$0.68 beats by $0.09
    Nov 12 Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
    Nov 9 Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
    Nov 8 Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Oct 30 Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
    Oct 9 Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Oct 8 Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings
    Oct 2 Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate
    Sep 15 Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
    Sep 9 Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024
    See more REPL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.97
    52 Week Low 4.92
    Average Volume 676,170
    200-Day Moving Average 9.09
    50-Day Moving Average 11.50
    20-Day Moving Average 11.84
    10-Day Moving Average 11.62
    Average True Range 0.65
    RSI (14) 45.05
    ADX 20.3
    +DI 15.57
    -DI 25.00
    Chandelier Exit (Long, 3 ATRs) 11.02
    Chandelier Exit (Short, 3 ATRs) 12.52
    Upper Bollinger Bands 12.91
    Lower Bollinger Band 10.76
    Percent B (%b) 0.22
    BandWidth 18.22
    MACD Line -0.11
    MACD Signal Line 0.07
    MACD Histogram -0.1721
    Fundamentals Value
    Market Cap 689.38 Million
    Num Shares 61.4 Million
    EPS -3.16
    Price-to-Earnings (P/E) Ratio -3.55
    Price-to-Sales 0.00
    Price-to-Book 1.13
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.04
    Resistance 3 (R3) 11.97 11.63 11.91
    Resistance 2 (R2) 11.63 11.42 11.67 11.86
    Resistance 1 (R1) 11.43 11.30 11.53 11.50 11.81
    Pivot Point 11.09 11.09 11.14 11.13 11.09
    Support 1 (S1) 10.89 10.88 10.99 10.96 10.65
    Support 2 (S2) 10.55 10.76 10.59 10.60
    Support 3 (S3) 10.35 10.55 10.56
    Support 4 (S4) 10.42